Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Seeking Alpha, Healthcare Asia Magazine, Yahoo Finance and KSL News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 48d ago.
Quick answers
Why is "Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Founday" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (15)
- Eli Lilly breaks ground on $6.5B Houston plant Axios · 48d ago
- Lilly CEO Dave Ricks says Foundayo winning new pill patients Yahoo Finance · 48d ago
- The company behind a new GLP-1 pill is betting $6.5 billion on Houston Houston Chronicle · 48d ago
- Eli Lilly breaks ground on $6.5B Houston plant, largest project of its kind in Texas history The Business Journals · 48d ago
- Eli Lilly is breaking ground in Houston on a facility planned for 2030 KHOU · 48d ago
- Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets TradingView · 48d ago
- Eli Lilly Stock (LLY) Rises After Company Provides Update on Obesity Pill Sales TipRanks · 48d ago
- Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up By Reuters Investing.com · 48d ago
- Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs Reuters · 48d ago
- Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets Seeking Alpha · 48d ago
- Obesity drugs market to grow 27% across 7MM by 2036 Healthcare Asia Magazine · 48d ago
- Lilly’s Obesity Access Push via Medicare Bridge Might Change The Case For Investing In Eli Lilly (LLY) Yahoo Finance · 48d ago
- Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up KSL News · 48d ago
- Lilly's Foundayo pill wins over a third of new patients, CEO says qz.com · 48d ago
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production CNBC · 48d ago
Topics
Related trends
Poland stunned as suspect with far-right views kills 6 in Kraków mass shooting
Poland mourns a rare mass killing in Kraków as authorities state the suspect held far-right views.
Berkshire Hathaway’s Operating Earnings Fall, Buybacks Rise
Berkshire Hathaway reports a drop in third-quarter earnings while significantly increasing its share buyback activity.
The AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%
Financial markets are signaling mounting distress across artificial intelligence infrastructure financing and mega-cap tech credits.
Union Pacific releases CEO video after federal regulators order it made public
Federal regulators order the release of a Union Pacific CEO video, disrupting merger plans and sparking industry-wide fallout.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
IonQ CEO Doubles Down on Vision for Quantum Dominance After Blowout Earnings
IonQ shares climbed after a financial report revealed record revenue and raised guidance following a volatile market period.